Regentis Biomaterials Slips 9% After Soaring 506% On Monday — Here's Why RGNT Stock Is Trending

Regentis Biomaterials (RGNT) surged 506% intraday on Monday to $9.40 before slipping 9.15% to $8.54 in after-hours trading. The volatility followed the company's announcement that it withdrew its Form F-1 registration statement and decided not to pursue a planned public offering. The regenerative medicine company, which develops tissue repair solutions including its Gelrin platform for orthopedic treatments, has a market cap of $48.69 million.